Drug Profile
NGD 912
Latest Information Update: 26 Jan 2001
Price :
$50
*
At a glance
- Originator Neurogen Corporation
- Developer Neurogen Corporation; Pfizer
- Class Anxiolytics
- Mechanism of Action GABA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 26 Jan 2001 Discontinued-II for Anxiety disorders in USA (Unknown route)
- 23 Jun 2000 Pfizer has merged with Warner-Lambert
- 27 Mar 2000 Phase-II clinical trials for Anxiety disorders in USA (Unknown route)